TuHURA Biosciences draws $1.5 million from Parkview revolving facility for general corporate use
In the pre-commercial phase of the biotech cycle, how a company bridges its cash requirements between milestones shapes the balance sheet as much as any pipeline result. TuHURA Biosciences, Inc. (Nasdaq: HURA), listed on the…
Key takeaways
- TuHURA Biosciences (Nasdaq: HURA) drew an additional $1,500,000 from its revolving credit facility with Parkview Holdings One LLC on September 2, 2026, disclosed in a Form 8-K filed September 4.
- The Parkview Loan Agreement, first executed April 21, 2026, carries a maximum availability of $50 million and matures April 21, 2031.
- TuHURA expects to use the September draw for general corporate purposes, with no specific programs or projects identified in the filing.
- Parkview Holdings One LLC is an affiliate of TuHURA's largest stockholder, and the company disclosed that competing interests could arise between Parkview and other shareholders.
- TuHURA disclosed that funds available under the Loan Agreement could prove insufficient to fund its operations and development programs as currently anticipated.
In the pre-commercial phase of the biotech cycle, how a company bridges its cash requirements between milestones shapes the balance sheet as much as any pipeline result. TuHURA Biosciences, Inc. (Nasdaq: HURA), listed on the Nasdaq Capital Market, drew an additional $1,500,000 from its revolving credit facility with Parkview Holdings One LLC on September 2, 2026, disclosing the transaction in a Form 8-K filed with the Securities and Exchange Commission on September 4.
The Loan Agreement with Parkview was first executed on April 21, 2026, with TuHURA disclosing that arrangement to the SEC via an 8-K filed the following day. The facility carries a maximum availability of $50 million and matures on April 21, 2031. TuHURA, a Nevada-incorporated company headquartered in Tampa, Florida, expects to apply the September draw toward general corporate purposes. No specific programs or projects were identified in the filing.
The revolving structure gives TuHURA optionality across the capital cycle. Rather than committing to a fixed-term instrument or accessing equity markets, the company can call on the facility as operational needs arise, within the $50 million ceiling and ahead of the 2031 maturity date.
Lender affiliation and disclosed risk
Parkview Holdings One LLC is an affiliate of TuHURA's largest stockholder. The company disclosed this relationship in the 8-K's forward-looking risk language, noting that competing interests could arise between Parkview and the company's other shareholders.
Dan Dearborn, chief financial officer, signed the filing on TuHURA's behalf. The company also disclosed that available funds under the Loan Agreement could prove insufficient to fund its operations and development programs to the extent currently anticipated. The filing directs investors to TuHURA's Annual Report on Form 10-K for fiscal year 2025, filed March 31, 2026, for a fuller accounting of operating risks, including the possibility that TuHURA may be unable to satisfy conditions for future drawdowns or maintain compliance with the facility's terms. That risk will define how much of the $50 million ceiling the company can access before April 2031.
Source · 來源